{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:37:41Z","timestamp":1790696261744,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.prrv.2023.06.001","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T21:49:25Z","timestamp":1686952165000},"page":"23-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["An innovative strategy for personalised medicine in a CFSPID case that evolved with time"],"prefix":"10.1016","volume":"47","author":[{"given":"J.","family":"Twynam-Perkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Lefferts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Urquhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2023.06.001_b0005","unstructured":"http:\/\/cftr2.org., (Accessed 15th March 2023)."},{"issue":"2","key":"10.1016\/j.prrv.2023.06.001_b0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","volume":"21","author":"de Poel","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.prrv.2023.06.001_b0015","first-page":"59","article-title":"CFTR modulator therapy for rare CFTR mutants","volume":"2","author":"Mergiotti","year":"2022","journal-title":"J Respir"},{"issue":"7","key":"10.1016\/j.prrv.2023.06.001_b0020","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/ppul.24764","article-title":"Ataluren\/ivacaftor combination therapy: two N-of-1 trials in cystic fibrosis patients with nonsense mutations","volume":"55","author":"Peabody Lever","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.prrv.2023.06.001_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/s41231-020-00060-3","article-title":"Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators","volume":"5","author":"van Mourik","year":"2020","journal-title":"Transl Med Commun"},{"issue":"344","key":"10.1016\/j.prrv.2023.06.001_b0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.prrv.2023.06.001_b0035","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.prrv.2023.06.001_b0040","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00383-015-3742-8","article-title":"Rectal suction biopsy for the diagnosis of Hirschsprung's disease: a systematic review of diagnostic accuracy and complications","volume":"31","author":"Friedmacher","year":"2015","journal-title":"Pediatr Surg Int"},{"issue":"10","key":"10.1016\/j.prrv.2023.06.001_b0045","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3390\/cells10102793","article-title":"Therapeutic approaches for patients with cystic fibrosis not eligible for current CFTR modulators","volume":"10","author":"Fajac","year":"2021","journal-title":"Cells"},{"issue":"13","key":"10.1016\/j.prrv.2023.06.001_b0050","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99385","article-title":"Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies","volume":"3","author":"Brewington","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.prrv.2023.06.001_b0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/jpm11050421","article-title":"Personalized medicine based on nasal epithelial cells: comparative studies with rectal biopsies and intestinal organoids","volume":"11","author":"Silva","year":"2021","journal-title":"J Personalized Med"},{"issue":"1","key":"10.1016\/j.prrv.2023.06.001_b0060","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2023.06.001_b0065","doi-asserted-by":"crossref","unstructured":"Chan, A.-W., Tetzlaff, JM., Gotzsche, PC., Altman, DG., Mann, H., Berlin, JA., et al., SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ: British Medical Journal, 2013. 346: e7586.","DOI":"10.1136\/bmj.e7586"},{"key":"10.1016\/j.prrv.2023.06.001_b0070","doi-asserted-by":"crossref","unstructured":"Lord-Bessen, J., Signorovitch, J., Yang M., Georgieva, M., Roydhouse, J., et al., Assessing the Impact of Open-Label Designs in Patient-Reported Outcomes: Investigation in Oncology Clinical Trials. JNCI Cancer Spectr, 2023.","DOI":"10.1093\/jncics\/pkad002"},{"issue":"apr10 1","key":"10.1016\/j.prrv.2023.06.001_b0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2674","article-title":"What is an \u201cn-of-1\u201d trial?","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ: British Medical Journal"},{"issue":"1","key":"10.1016\/j.prrv.2023.06.001_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-15-456","article-title":"Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials","volume":"15","author":"Kahan","year":"2014","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.prrv.2023.06.001_b0085","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054223000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:36:22Z","timestamp":1761507382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054223000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":17,"alternative-id":["S1526054223000374"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2023.06.001","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An innovative strategy for personalised medicine in a CFSPID case that evolved with time","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2023.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}